Expression of galectin‐3 involved in prognosis of patients with hepatocellular carcinoma

Matsuda, Yasunori; Yamagiwa, Yoko; Fukushima, Koji; Ueno, Yoshiyuki; Shimosegawa, Tooru

doi:10.1111/j.1872-034x.2008.00387.x

Cited by 72 publications

(77 citation statements)

References 46 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levels as high as 50 mg/ml have been detected in the BAL fluid of mice after infection with Streptococcus pneumoniae . In addition, Gal-3 expression has been linked to increased malignancy in a number of tumours (Inohara et al 2008, Saussez et al 2008 and may be of use as a marker for determining stages of certain tumours (Balasubramanian et al 2008, Matsuda et al 2008. The role of Gal-3 in innate immunity is supported by studies showing that neutrophil and macrophage recruitment is attenuated in in vivo models of peritonitis conducted in mice nullified for this lectin (Colnot et al 1998b.…”

Section: Actions Of Exogenous Galectin-3mentioning

confidence: 60%

Endogenous galectins and the control of the host inflammatory response

Norling¹,

Perretti²,

Cooper³

2009

Journal of Endocrinology

View full text Add to dashboard Cite

A new era of research is being devoted to deciphering endogenous mediators and mechanisms that are in place to resolve the inflammatory response. Accruing evidence indicates that galectins fall into this category of immunoregulatory mediators signifying their use as prospective novel anti-inflammatory agents. The focus of this review is to depict the immunoregulatory bioactivities of three members of the galectin superfamily, Galectin (Gal)-1, Gal-3 and Gal-9.Emphasis is given to the studies investigating the properties of these endogenous lectins. Gal-1, Gal-3 and Gal-9 are emerging as pertinent players in the modulation of acute and chronic inflammatory diseases, autoimmunity and cancer, and thus being increasingly recognised as molecular targets for innovative drug discovery.

show abstract

Section: Actions Of Exogenous Galectin-3mentioning

confidence: 60%

Endogenous galectins and the control of the host inflammatory response

Norling¹,

Perretti²,

Cooper³

2009

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Previous studies concerning the relationship between the expression of galectin-3 and prognosis in solid cancers showed somewhat conflicting results. 13,14,19,20 Regarding the hematological malignancies, higher expression of LGALS3 in peripheral blood mononuclear cells is observed in patients with indolent chronic lymphocytic leukemia compared with those with progressive disease. 41 In contrast, endothelial expression of galectin-3 is identified as a bad prognostic factor in primary central nervous system lymphoma, 42 and increased serum galectin-3 expression may indicate a worse prognosis in diffuse large B-cell lymphomas.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 Alterations of galectin-3 expression are often seen in cancers and may contribute to tumorigenesis, cancer progression, angiogenesis, and metastasis. 1,10,11 Increased galectin-3 expression has been shown to be correlated with tumor progressions 12 and poor prognosis in some cancers, such as hepatocellular carcinoma 13 and primary cutaneous melanoma. 14 For diffuse large B-cell lymphomas, galectin-3 is an antiapoptotic factor, 15 and its overexpression is associated with a worse prognosis.…”

Section: Introductionmentioning

confidence: 99%

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia

Cheng

Hou

Lee

et al. 2013

Blood

View full text Add to dashboard Cite

show abstract

“…There have been numerous reports describing a role for galectin-3 in tumor progression and metastasis ( 17 , 30 , 31 ); however, there are confl icting data about the value of galectin-3 as a prognostic factor either in gene expression profi ling of human tumor samples or by monitoring protein levels in serum (32)(33)(34)(35). In Fig.…”

Section: St6galnac2 Expression Determines Responsiveness To Galectin-mentioning

confidence: 99%

An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor

et al. 2014

View full text Add to dashboard Cite

To interrogate the complex mechanisms involved in the later stages of cancer metastasis, we designed a functional in vivo RNA interference (RNAi) screen combined with next-generation sequencing. Using this approach, we identifi ed the sialyltransferase ST6GalNAc2 as a novel breast cancer metastasis suppressor. Mechanistically, ST6GalNAc2 silencing alters the profi le of O -glycans on the tumor cell surface, facilitating binding of the soluble lectin galectin-3. This then enhances tumor cell retention and emboli formation at metastatic sites leading to increased metastatic burden, events that can be completely blocked by galectin-3 inhibition. Critically, elevated ST6GALNAC2 , but not galectin-3, expression in estrogen receptor-negative breast cancers signifi cantly correlates with reduced frequency of metastatic events and improved survival. These data demonstrate that the prometastatic role of galectin-3 is regulated by its ability to bind to the tumor cell surface and highlight the potential of monitoring ST6GalNAc2 expression to stratify patients with breast cancer for treatment with galectin-3 inhibitors. SIGNIFICANCE:RNAi screens have the potential to uncover novel mechanisms in metastasis but do not necessarily identify clinically relevant therapeutic targets. Our demonstration that the sialyltransferase ST6GalNAc2 acts as a metastasis suppressor by impairing binding of galectin-3 to the tumor cell surface offers the opportunity to identify patients with breast cancer suitable for treatment with clinically well-tolerated galectin-3 inhibitors. Cancer Discov; 4(3);

show abstract

Expression of galectin‐3 involved in prognosis of patients with hepatocellular carcinoma

Abstract: Galectin-3 expression was involved in the tumor progression and related to the prognosis of HCC. Our observations suggested that galectin-3 could be a novel tumor marker and therapeutic target.

Cited by 72 publications

References 46 publications

Endogenous galectins and the control of the host inflammatory response

Endogenous galectins and the control of the host inflammatory response

Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia

An In Vivo Functional Screen Identifies ST6GalNAc2 Sialyltransferase as a Breast Cancer Metastasis Suppressor

Contact Info

Product

Resources

About